Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Moxifloxacin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture~* Starting treatment with MFX in a dose of 400 mg as part of their TB treatment~Exclusion Criteria:~* Contra-indication for MFX~* Baseline QTc-interval \> 450 msec~* History of resuscitation~* History of ventricular tachycardia (including Torsades de Pointes)~* Family history of sudden cardiac death or Torsades de Pointes~* Additional risk factors for Torsades de Pointes (including known heart failure, Left ventricular hypertrophy)~* Use of concomitant treatment with QT/QTc prolonging drugs (including anti-dysrhythmics class IA and III, antipsychotics, tricyclic antidepressants or the antihistaminic drug terfenadine)~* Abnormal electrolytes (K, Mg, Na, Ca)~* Abnormal cardiac repolarisation on screening/baseline ECG~* History of adverse events to fluoroquinolones~* HIV co-infection~* RIF treatment during last 3 weeks before start of the study. After a washout period of 3 weeks the patient can be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): Moxifloxacinin escalating dose

Based on this trial design, predict the completion outcome and termination type (if applicable).